StreetAlpha.app
Home › Stocks › SIBN

SI-BONE, Inc. (SIBN)

Healthcare
$23.16
▼ −1.07%
LAST CLOSE · NOV 17

SI-BONE makes surgical and medical devices sold to surgeons and other healthcare providers. It last closed at $23.16 on Nov 17, down 1.07% on the day. The average 12-month price target from 4 analysts is $25.00 (+7.9% from the last close), with a high of $26.00 and a low of $23.00. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (4 buy, 0 hold, 0 sell). In the past 30 days there were 1 dark pool print totaling $622K, the largest $622K.

AI Auto Pilots
Is SIBN in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$220.7M
+14.0% vs a year ago
Net income
−$13.7M
−6.2% margin
EPS (diluted)
−$0.31
Free cash flow
−$4.2M
−1.9% margin
Valuation
Market cap
$1.0B
45.1M shares
P/E
–
No P/E while losing money
Price to sales
4.7
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$35.3M
At Sep 30
Debt
$35.7M
At Sep 30
Shareholder equity
$184.7M
Shares outstanding
45.1M
At Oct 28
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $90.2M$90.2MFY2021FY2022: $106.4M$106.4MFY2022FY2023: $138.9M$138.9MFY2023FY2024: $167.2M$167.2MFY2024FY2025: $200.9M$200.9MFY2025

From SIBN's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 3). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 4 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
4firms
4 Buy0 Hold0 Sell
Each firm's latest rating on SIBN in the past 90 days
Average 12-month target
$25.00
▲ 7.9% upside

Based on 4 analysts who set a price target on SIBN in the past 90 days. The average target is $25.00, with a high of $26.00 and a low of $23.00, compared with the last close of $23.16.

Low $23.00Avg $25.00High $26.00
Blue marker: last close $23.16
Highest target$26.00
Average target$25.00
Lowest target$23.00
Latest rating changes
UBSTarget raised
Nov 3Buy$25 → $26
TD CowenTarget raised
Nov 3Buy$20 → $23
NeedhamMaintained
Nov 3Buy$26
Truist SecuritiesTarget raised
Oct 14Buy$23 → $25
UBSTarget raised
Aug 4Buy$24 → $25
DateFirmActionRatingPrice target
Nov 3UBSTarget raisedBuy$25 → $26
Nov 3TD CowenTarget raisedBuy$20 → $23
Nov 3NeedhamMaintainedBuy$26
Oct 14Truist SecuritiesTarget raisedBuy$23 → $25
Aug 4UBSTarget raisedBuy$24 → $25
Loading…

Technical Analysis

SIBN · as of the Nov 17 close · updated after every close
Uptrend

The stock is 1% above its 20 day and 11% above its 50 day average. It is 27% above its 200 day average, so the longer trend is still up. Momentum is neutral (RSI 55). The nearest support is the 20 day average at $22.97, and the nearest resistance the Pivot at $23.19.

Short trendBullish
Long trendBullish
MomentumNeutral
StretchNormal
VolatilityHigh, 4.8%/day
Key levels
$25.9252 week high+11.9%
$25.92Swing high (Nov 4)+11.9%
$23.43Pivot R1+1.2%
$23.19Pivot+0.1%
$23.16Last close
$22.9720 day average−0.8%
$22.91Pivot S1−1.1%
$20.5750 day average−11.2%
$19.36100 day average−16.4%
$19.19Swing low (Oct 16)−17.1%
$16.82200 day average−27.4%
$11.4852 week low−50.4%
Indicators
RSI (14)54.54Middle of its rangeNeutral
MACD1.03Below its signal lineBearish
Stochastic62.3Middle of its rangeNeutral
ADX (14)32.0Trending up
Williams %R-40.3Oversold below −80, overbought above −20Neutral
CCI (20)13.5Oversold below −100, overbought above 100Neutral
Rate of change−2.6%Change over 10 sessionsBearish
ATR (14)$1.12Typical daily range, 4.8% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for SIBN

What happened before

See how SIBN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow SIBN usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How SIBN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in SIBN in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
1
Notional
$622K
Largest print
$622K
Loading…

SIBN Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲97 buying vs 68 selling
  • ▲Held by funds +1.0 pts
  • ▲Funds holding +11
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding179168+6.5%
In funds' top 10220.0%
Held by funds107.8%106.8%+1.0 pts
New / increased32 / 6519 / 81−3.0%
Reduced / sold out46 / 2246 / 29−9.3%
Put/call ratio0.000.99−100.0%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See SIBN institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SIBN is in one of them and how their past SIBN trades turned out.

SIBN in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered SIBN in an article yet. Here's the latest on the wider market.

About SI-BONE

SI-BONE makes surgical and medical devices that are used in procedures performed by surgeons. Its customers include physicians and other healthcare providers who use its products with patients. The company is headquartered in San Jose, California.

Headquarters
San Jose, CA
Founded
2008